Invention Grant
- Patent Title: Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis
-
Application No.: US16473878Application Date: 2018-01-05
-
Publication No.: US10669266B2Publication Date: 2020-06-02
- Inventor: John Cijiang He , Ruijie Liu , Bhaskar Das , Wenzhen Xiao , Zhengzhe Li , Kyung Lee
- Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI , UNIVERSITY OF KANSAS
- Applicant Address: US NY New York US KS Lawrence
- Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,UNIVERSITY OF KANSAS
- Current Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,UNIVERSITY OF KANSAS
- Current Assignee Address: US NY New York US KS Lawrence
- Agency: Heslin Rothenberg Farley & Mesiti, P.C.
- International Application: PCT/US2018/012512 WO 20180105
- International Announcement: WO2018/129274 WO 20180712
- Main IPC: C07D271/04
- IPC: C07D271/04 ; C07D271/06 ; C07D271/08 ; C07D271/107 ; C07D413/04 ; C07F5/04 ; A61P13/12 ; C07D413/14 ; C07F5/02 ; C12N9/99
Abstract:
Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds have the following structure: in which Z is an oxadiazole. The compounds disclosed are useful in treatment of fibrotic disease, particularly renal fibrosis, and similar diseases associated with the dysregulation of the HIPK2/Smad3 signaling pathway.
Public/Granted literature
- US20190352292A1 OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS Public/Granted day:2019-11-21
Information query
